Back to News
Market Impact: 0.4

RBC Capital raises ASML stock price target on strong EUV demand

ASMLBCS
Corporate EarningsCorporate Guidance & OutlookAnalyst EstimatesAnalyst InsightsTechnology & InnovationCompany Fundamentals
RBC Capital raises ASML stock price target on strong EUV demand

RBC Capital raised its price target on ASML to EUR 1,700 from EUR 1,625 and kept an Outperform rating, citing stronger-than-expected Q1 results and improving visibility into 2026-2028 growth. ASML lifted its fiscal 2026 revenue outlook by 4% and now expects EUR 36-40 billion in full-year 2026 revenue, while EUV demand remains ahead of supply with output projected at 60 tools in 2026 and more than 80 in 2027. Analyst views remain broadly positive, with Barclays at EUR 1,500, BofA at EUR 1,598, and Jefferies at EUR 1,260.

Analysis

The market is implicitly re-rating ASML from a cyclical semiconductor equipment name to a scarce-capacity infrastructure bottleneck. The key second-order effect is that every incremental EUV tool shipped through 2027 amplifies pricing power not just for ASML, but for the leading-edge logic and memory customers that can secure wafers early; that tends to widen the gap between capex winners and everyone forced to wait in line. If EUV output really ramps as guided, the supply constraint shifts from demand uncertainty to execution risk, which is usually a healthier setup for the stock and for the most advanced foundry players. The near-term risk is not demand, but the timing mismatch between backlog conversion and shipping capacity. That means the stock can still wobble over the next 1-2 quarters if quarterly bookings or revenue timing disappoint versus elevated buy-side expectations, even if the 2027-28 setup remains intact. Another subtle risk is that China normalization is now framed as ‘de-risked,’ which can lull investors into underestimating how much of the valuation expansion already embeds a cleaner geopolitics path. The contrarian angle is that consensus may be extrapolating a straight-line 2027 growth story without adequately discounting elasticity in customer capex. If GenAI ROI takes longer to prove out, foundry and memory spending could pause after the current cycle, creating a digestion period in 2H26 even with strong structural demand. That makes the setup attractive for owning strength into guide raises, but less attractive chasing a crowded, high-multiple name after a large run unless the position is paired against less differentiated semi capex exposure.